Novo Nordisk A/S, Share Repurchase Programme

Bagsværd, Denmark, 16 May 2022

On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022.

Under the programme initiated 3 May 2022, Novo Nordisk will repurchase B shares for an amount up to DKK 4.4 billion in the period from 4 May 2022 to 2 August 2022.

Since the announcement of the programme, the following transactions have been made …

  Number of
B shares		 Average
purchase price		 Transaction
value, DKK
4 May 2022 90,000 791.95 71,275,769
5 May 2022 85,000 794.61 67,541,429
6 May 2022 90,000 780.81 70,272,636
9 May 2022 90,000 768.69 69,182,470
10 May 2022 90,000 755.70 68,013,041
11 May 2022 94,689 745.71 70,610,824
12 May 2022 95,000 742.90 70,575,746
Accumulated under the programme 634,689   487,471,914

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

Transactions related to Novo Nordisk’s incentive programmes have resulted in a net transfer from Novo Nordisk of 30,489 B shares in the period from 4 May 2022 to 12 May 2022. The shares in these transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 12,696,381 B shares of DKK 0.20 as treasury shares, corresponding to 0.6 percent of the share capital. The total amount of A and B shares in the company is 2,280,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 24 billion during a 12-month period beginning 2 February 2022. As of 12 May 2022, Novo Nordisk has since 2 February 2022 repurchased a total of 10,956,818 B shares at an average share price of DKK 756.54 per B share equal to a transaction value of DKK 8,289,276,935.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 49,300 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, Linkedin, and Youtube.